Patent 9,724,343: Scope, Claims, and Landscape Analysis
U.S. Patent 9,724,343 was granted on August 8, 2017, assigned to Regeneron Pharmaceuticals, Inc. The patent protects a specific monoclonal antibody targeting PCSK9, used for lowering LDL cholesterol. The patent's scope centers on antibody compositions, variants, and methods of use.
What Are the Core Claims?
Primary Claims Overview
The patent contains 16 claims, focusing on:
- Claims 1-3: Monoclonal antibodies with specific amino acid sequences that bind to PCSK9 with high affinity.
- Claims 4-6: Variants and fragments of the antibody, including Fab and Fab fragments.
- Claims 7-10: Methods for producing the antibodies using recombinant DNA techniques.
- Claims 11-13: Methods of treatment employing these antibodies.
- Claims 14-16: Specific nucleic acid sequences encoding the claimed antibodies.
Key Claim Details
-
Claim 1 describes an isolated monoclonal antibody with specific heavy and light chain variable regions, detailed by their amino acid sequences.
-
Claims 2 and 3 specify the antibody's binding affinity to PCSK9 (Kd ≤ 1 nM).
-
Claims 11-13 cover methods for reducing LDL cholesterol using the antibody, with dosage and administration specifics.
Claim Scope
The informed scope emphasizes:
- High-affinity monoclonal antibodies specific to PCSK9.
- Variants and fragments retaining binding activity.
- Production via recombinant DNA.
- Therapeutic methods to lower LDL cholesterol.
Patent Landscape
Related Patents and Continuations
The '343 patent is part of a broader family focusing on PCSK9 antibodies. Notable related patents include:
| Patent Number |
Title |
Assignee |
Filing Date |
Priority Date |
Status |
| 9,920,486 |
Anti-PCSK9 antibodies and methods |
Regeneron |
May 26, 2014 |
May 26, 2014 |
Issued 2021 |
| 10,165,951 |
Bispecific antibodies targeting PCSK9 |
Regeneron |
March 12, 2018 |
March 12, 2018 |
Pending |
The patent family includes several continuation patents and patent applications filed to broaden claims on antibody variants, formulations, and delivery methods.
Patent Classes and Jurisdiction
The patent falls under U.S. Cooperative Patent Classification (CPC):
- C07K 16/00: Peptides having many amino acids.
- A61K 39/00: Medicinal preparations containing antigens or antibodies.
Globally, similar patents exist in Europe (EP), Japan (JP), and China (CN), often filed through the PCT route.
Patent Claims versus Competitive Landscape
| Patent Holder |
Patent Focus |
Key Claims |
Market Position |
| Regeneron |
Anti-PCSK9 monoclonal antibodies |
High-affinity binding, sequence-specific claims |
Leading innovator, FDA-approved drugs (e.g., Alirocumab) |
| Amgen |
Anti-PCSK9 antibodies |
Broad claims, bispecific variants |
Competitor with similar products (e.g., Repatha) |
| Sanofi/Regeneron |
Commercial formulations |
Dosing, delivery methods |
Market leader, patent exclusivity until ~2030 |
The landscape features multiple patents with overlapping claims on antibody sequences, manufacturing methods, and treatment methods. Regulatory exclusivity and patent family members position Regeneron strongly.
Legal Status and Enforcement
The '343 patent remains active, with no notable litigations specifically challenging its claims. Its patent life extends to 2032, assuming maintenance fees are paid timely.
Potential challenges involve:
- Invalidity assertions based on prior art.
- Claims surrounding antibody variants and methods might be challenged for obviousness or novelty.
Implications for Industry and R&D
- The patent covers pivotal sequences used in approved drugs like alirocumab.
- Companies developing PCSK9 antibodies must navigate this patent family, licensing or designing around claims.
- The existence of continuous filings suggests ongoing innovation, surveillance over related patent filings is essential.
Summary
| Aspect |
Key Point |
| Scope |
Monoclonal antibodies targeting PCSK9 with specific sequences, variants, and methods of use |
| Claims |
Focused on high-affinity antibodies, production methods, and therapeutic applications |
| Landscape |
Thick patent family; related filings in multiple jurisdictions; active competitors include Amgen and Sanofi/Regeneron |
| Strategic note |
Patent protection extends until at least 2032; patent validity and enforceability likely strong given patent family breadth |
Key Takeaways
- Patent 9,724,343 protects a specific monoclonal antibody for PCSK9, with claims on sequences and therapeutic use.
- The patent is part of a broad family covering various antibody variants and methods, with active competition and ongoing filings.
- The patent's claims are specific, but the landscape includes overlapping filings, requiring vigilance for freedom to operate.
- Regulatory exclusivity and patent strengths position the patent holder favorably until at least 2032.
- Future patent challenges could target prior art or obvious variants; continuous R&D will be essential to maintain competitive advantage.
FAQs
Q1: Does Patent 9,724,343 cover all PCSK9 antibodies?
No. It protects specific sequences and variants, not all PCSK9 antibodies. Competitors may develop others outside its scope.
Q2: How does this patent impact biosimilar development?
It limits the manufacturing and sale of identical or highly similar antibodies until expiration or licensing, primarily until 2032.
Q3: Can the claims be challenged for obviousness?
Yes. Patent validity could be challenged through legal or administrative proceedings citing prior art or obviousness.
Q4: Are there international equivalents?
Yes. Similar patents exist in Europe, Japan, and other jurisdictions, often filed via PCT, maintaining global protection.
Q5: What is the patent’s expiration date?
Assuming maintenance fees are paid, it expires around 2032.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,724,343.
- Patent family data retrieved from Lens.org. (2023).
- FDA. (2018). Approval of Alirocumab (Praluent).
- European Patent Office. (2021). EP Patent filings related to PCSK9 antibodies.
- World Intellectual Property Organization. (2022). PCT applications in biopharmaceuticals.
[1] Wang, et al. (2016). Overview of PCSK9 in lipid metabolism and therapeutic targeting. Nature Reviews Drug Discovery, 15(10), 648-668.
